32 reports

  • OCT 03, 2013: LUPIN LAUNCHES GENERIC ZYMAXID OPHTHALMIC SOLUTION IN THE US
  • AUG 28, 2013: LUPIN RECEIVES FDA APPROVAL FOR GATIFLOXACIN EYE DROPS

Bacterial Conjunctivitis - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Pipeline Review, H1 2018, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape. Bacterial...

  • Eye Disease
  • Ophthalmic Solution
  • United States
  • Litigation And Patent
  • InSite Vision Incorporated
  • OCT 03, 2013: LUPIN LAUNCHES GENERIC ZYMAXID OPHTHALMIC SOLUTION IN THE US
  • JUL 01, 2013: LUPIN GETS FDA TENTATIVE APPROVAL FOR GATIFLOXACIN EYE DROPS

Bacterial Conjunctivitis - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2017, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape. Bacterial conjunctivitis...

  • Eye Disease
  • Ophthalmic Solution
  • United States
  • Litigation And Patent
  • InSite Vision Incorporated
  • 6.2.3 MUCOSTA OPHTHALMIC SOLUTION (REBAMIPIDE)
  • PRODUCT PROFILE - LIFITEGRAST

PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which...

  • Ophthalmic Solution
  • Market Size
  • Allergan plc
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Clinical Trial profile. 41 Trial Title
  • Clinical Trial profile. 60 Trial Title

Allergic Conjunctivitis Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Allergic Conjunctivitis Global Clinical Trials Review, H1, 2017" provides an overview of Allergic Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on...

  • Ophthalmic Solution
  • OTC
  • Respiratory Treatment
  • World
  • Product Initiative
  • Clinical Trial profile. 465
  • Clinical Trial profile. 102

Conjunctivitis Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Conjunctivitis Global Clinical Trials Review, H1, 2017" provides an overview of Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Conjunctivitis. Report includes...

  • Clinical Trial
  • Ophthalmic Solution
  • Pharmaceutical
  • Therapy
  • World
  • 11.3 NOVARTIS AG
  • Joint Venture

The global topical drug delivery market is poised to reach USD 125.88 billion by 2021 from USD 92.40 billion in 2016, growing at a CAGR of 6.4% from 2016 to 2021. Major factors driving the growth of this market are the high incidence of burn injuries, rising geriatric population, and increasing incidence of diabetes. The topical drug...

  • Hospital
  • Ophthalmic Solution
  • North America
  • United States
  • Market Size
  • Clinical Trial profile. 27 Trial Title
  • Clinical Trial profile. 175 Trial Title

Conjunctivitis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Conjunctivitis Global Clinical Trials Review, H2, 2016" provides an overview of Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Conjunctivitis. Report includes...

  • Allergy Drug
  • Eye Disease
  • Ophthalmic Solution
  • OTC
  • World
  • KEY M&A
  • Vendor landscape

About Bacterial Conjunctivitis Drugs Bacterial conjunctivitis, which affects either one or both the eyes, is an extremely contagious eye condition wherein the conjunctiva is infected. Staphylococci, streptococci, gonococci, and Chlamydia are some of the causative agents of bacterial conjunctivitis. Extremely pathogenic bacteria such...

  • Ophthalmic Solution
  • Akorn, Inc.
  • Alcon, Inc.
  • Allergan plc
  • Bausch & Lomb Incorporated
  • Strengths
  • Scope of the report

About Conjunctivitis Conjunctivitis, also called pink eye or Madras eye, is an infection in or inflammation of the conjunctiva. It affects either one or both a person's eyes and can be the result of an allergy, bacteria, or a virus. Allergens such as smoke, pollen, dust mites, eye drops, cosmetics, and perfumes can lead to conjunctivitis....

  • Ophthalmic Solution
  • Ophthalmology
  • Akorn, Inc.
  • Alcon, Inc.
  • Allergan plc
  • XENCOR INC
  • Allergic Conjunctivitis - Drug Profiles

The drug candidate is a topical ophthalmic solution containing high concentrations of hypochlorous acid as the active ingredient.

  • Ophthalmic Solution
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • APR 27, 2017: NICOX FIRST QUARTER 2017 BUSINESS UPDATE AND CASH POSITION
  • MAR 31, 2017: NICOX: BUSINESS UPDATE AND 2016 FINANCIAL RESULTS

VYZULTATM (latanoprostene bunod ophthalmic solution), ##. ##% Approved by the U. S.

  • Medical Device
  • Ophthalmic Solution
  • United States
  • Company
  • NicOx S.A.

In July, Bausch + Lomb conducted a voluntary recall of a single lot of Murocel Methylcellulose Lubricant Ophthalmic Solution, USP ##%, within the US.

  • Ophthalmic Solution
  • Ophthalmology
  • United States
  • Company
  • Bausch & Lomb Incorporated
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Mucosta

Dry Eye Syndrome - US Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially...

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Implementing inorganic growth strategies Advancing its pipeline through increased investment in R&D
  • Vendor landscape

It is a polyvinyl alcohol ophthalmic solution, which consists of ##. ##% ocular lubricant sterile solution.

  • Ophthalmic Solution
  • Akorn, Inc.
  • Alcon, Inc.
  • Allergan plc
  • Bausch & Lomb Incorporated
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Lifitegrast

Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially...

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Lifitegrast

Dry Eye Syndrome - Japan Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially...

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Tavilermide

Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially...

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • 5.2.3 Mucosta ophthalmic solution (rebamipide)
  • Product Profile - Lifitegrast

Dry Eye Syndrome - 5EU Drug Forecast and Market Analysis to 2024 Summary Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially...

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • JUL 22, 2016: VALEANT PHARMACEUTICALS RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA
  • BAUSCH & LOMB ENTERS INTO LICENSING AGREEMENT WITH PARAGON BIOTECK FOR PHENYLEPHRINE

Summary Bausch & Lomb Inc (Bausch & Lomb), a subsidiary of Valeant Pharmaceuticals International Inc, is a vision-care company with focus on the protection, enhancement and restoration of eyesight. It offers over-the-counter supplements, eye care products, contact lenses, ophthalmic pharmaceuticals, lens care products,...

  • Ophthalmic Solution
  • Pharmaceutical
  • United States
  • M&A
  • Bausch & Lomb Incorporated
  • BAUSCH & LOMB ENTERS INTO LICENSING AGREEMENT WITH PARAGON BIOTECK FOR PHENYLEPHRINE

Phenylephrine Hydrochloride Ophthalmic Solution, USP ##. ##% and ##% is an alpha-## adrenergic receptor agonist used for dilation of the pupil due to its vasoconstrictor and mydriatic action.

  • Ophthalmic Solution
  • Ophthalmology
  • United States
  • M&A
  • Bausch & Lomb Incorporated
  • CETIRIZINE HYDROCHLORIDE - DRUG PROFILE
  • Regulatory Details

The drug candidate is a topical ophthalmic solution.

  • Ophthalmic Solution
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

The company offers near vision solutions and develops ophthalmic medical devices.

  • Ophthalmic Solution
  • United States
  • Company
  • Market Segment
  • Hoya Corporation

The company has started providing ophthalmic solutions like Zeiss Ophthalmic Data Management Solution, Zeiss Toric Solution & Zeiss Refractive Laser Solution.

  • Ophthalmic Solution
  • Abbott Medical Optics, Inc.
  • Alcon, Inc.
  • Carl Zeiss Meditec AG
  • Essilor group

Thus they are known as one step peroxide solutions.

  • Ophthalmic Solution
  • Pharmaceutical
  • North America
  • Forecast
  • Valeant Pharmaceuticals International, Inc.

For instance, the recent approval of Zerviate (cetirizine) for the treatment of allergic conjunctivitis in 2017 and Humira (adalimumab) and Xiidra (lifitegrast) in 2016 as ophthalmic solutions for the treatment of uveitis and dry eyes are expected to boost the market growth.

  • Ophthalmic Solution
  • OTC
  • Pharmaceutical
  • United States
  • Forecast

The prominent features of this report are - ##.

  • Allergy Drug
  • Ophthalmic Solution
  • OTC
  • World
  • Product Initiative

Multipurpose solutions and one step peroxide solutions are covered under this segment.

  • Healthcare
  • Ophthalmic Solution
  • North America
  • United States
  • Alcon, Inc.
  • TRENDS

EYE CARE IN COLOMBIA Euromonitor International September 2016 Passport I LIST OF CONTENTS AND TABLES Passport II Passport ## EYE CARE IN COLOMBIA - CATEGORY ANALYSIS TRENDS Eye care sees an increase of ##% in current value terms in 2016, to reach Col$##. ## billion Laboratorios Alcon de Colomb

  • Ophthalmic Solution
  • OTC
  • Colombia
  • Demand

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Ophthalmic Solution
  • OTC
  • Pharmaceutical
  • World
  • Product Initiative
  • Allergan Inc Business Segmentation by Revenue in %, 2013
  • 8.3 Allergan Inc.

Scope of the Report The report titled “Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)” provides an insight into the glaucoma treatment market over the years with a special focus on major categories- pharmaceuticals and devices. The report includes detailed information on market size and share by type of...

  • Ophthalmic Solution
  • Alcon, Inc.
  • Allergan plc
  • Bausch & Lomb Incorporated
  • Merck & Co., Inc.